STAB - Statera slides 18% as biopharma proposes stock offering
Statera Biopharma (NASDAQ:STAB) said it has started public stock offering while the actual size and other terms remain undisclosed. The offering of units will comprise of one common share and one warrant to purchase additional share each, and pre-funded units. EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering. STAB stock fell 18% in postmarket trading. Earlier (Feb. 21): Statera Biopharma reports prelim 2021 revenue of $1.49M
For further details see:
Statera slides 18% as biopharma proposes stock offering